How does this decision affect Wegovy?

Wegovy loses its commercial advantage within CVS Caremark's network, as it now competes on equal footing with Eli Lilly's drugs.

Which Eli Lilly drugs are affected?

Zepbound (tirzepatide) and Foundayo (a combination of tirzepatide and cagrilintide). Foundayo is still investigational and not FDA-approved.

Why is this decision important for investors?

It removes a competitive advantage for Novo Nordisk and gives Eli Lilly broader access, potentially impacting market shares and future revenues.

CVS Decision Reshapes GLP-1 Obesity Drug Competition

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage.

By: Wrqti Editorial

May 30, 2026

2 min read

Source: Simply Wall St.

CVS Caremark, the pharmacy benefit manager of CVS Health (NYSE: CVS), has announced it will grant preferred formulary status to Eli Lilly's (NYSE: LLY) Zepbound and Foundayo alongside Novo Nordisk's Wegovy. This move eliminates the previous commercial advantage Wegovy held within CVS Caremark's coverage of GLP-1 obesity drugs.

Details

Previously, Wegovy enjoyed exclusive preferred formulary status within CVS Caremark's network, giving it a clear competitive edge. Now, all three drugs—Wegovy, Zepbound, and Foundayo—will have equal access and coverage.

Context

This decision comes amid intense competition between Novo Nordisk and Eli Lilly in the booming GLP-1 drug market. Wegovy is an approved weight-loss drug, while Zepbound (tirzepatide) and Foundayo (a combination of tirzepatide and cagrilintide) are Lilly's latest offerings. Foundayo is an investigational drug not yet approved by the FDA.

What This Means for Investors

The decision removes Novo Nordisk's competitive edge within CVS Caremark's network, potentially impacting its market share. For Eli Lilly, the inclusion of its drugs expands its reach and strengthens its competitive position. Investors should monitor regulatory developments for Foundayo and competitive responses from other players.

Frequently Asked Questions

CVS Caremark has granted preferred formulary status to Eli Lilly's Zepbound and Foundayo alongside Novo Nordisk's Wegovy, ending Wegovy's previous exclusive advantage.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.